TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3327677

Group type: EXPERIMENTAL
Intervention: Felodipine 5mg twice daily
Number of subjects: 133

Group type: COMPARATOR
Intervention: Moduretic mite every morning
Number of subjects: 133

Group type: COMPARATOR
Intervention: Moduretic (after dose increase)
Number of subjects: 133
Study: 29674706

Group type: EXPERIMENTAL
Intervention: Risk stratification using both fasting plasma glucose and HbA1c data
Number of subjects: 10000

Group type: EXPERIMENTAL
Intervention: Paired baseline measurements of fasting plasma glucose and HbA1c
Number of subjects: 10000
Study: 25702630

Group type: EXPERIMENTAL
Intervention: Stepped-down weight loss intervention
Number of subjects: 106

Group type: COMPARATOR
Intervention: Enhanced usual care (EUC)
Number of subjects: 106
Study: 24884877

Group type: EXPERIMENTAL
Intervention: Clinical network-based intervention to improve uptake of guideline recommended care for men with high-risk prostate cancer following surgery.
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Clinicians' knowledge and attitudes assessed through surveys.
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Process outcome measures assessed through document review.
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Semi-structured interviews conducted to elucidate mechanisms of change.
Number of subjects: 9
Study: 22709990

Group type: EXPERIMENTAL
Intervention: Chester step test (CST)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Modified incremental step test (MIST)
Number of subjects: 32
Study: 20421547

Group type: EXPERIMENTAL
Intervention: Panel of four kallikreins (total PSA, free PSA, intact PSA, hK2)
Number of subjects: 2914

Group type: EXPERIMENTAL
Intervention: Application of the kallikrein panel to 1,000 men with elevated PSA
Number of subjects: 2914
Study: 18061415

Group type: EXPERIMENTAL
Intervention: Mixed (aerobic and resistance) exercise programme (150 min/week) prescribed and supervised for 12 months
Number of subjects: 606

Group type: COMPARATOR
Intervention: Conventional care including exercise counselling
Number of subjects: 606

Group type: EXPERIMENTAL
Intervention: Mixed (aerobic and resistance) exercise programme
Number of subjects: 606
Study: 16086611

Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 732

Group type: EXPERIMENTAL
Intervention: SSRIs (fluoxetine, sertraline, paroxetine)
Number of subjects: 732

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 732
Study: 11338291

Group type: EXPERIMENTAL
Intervention: Nutrilon Pepti
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Profylac
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Nan HA
Number of subjects: 32
Study: 9103485

Group type: EXPERIMENTAL
Intervention: Hydrocodone (10 mg, 15 mg, and 22.5 mg p.o.) after placebo or quinidine (100 mg) pretreatment
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Quinidine (100 mg) pretreatment
Number of subjects: 25
Study: 7942523

Group type: COMPARATOR
Intervention: t‐PA plus saline solution (group 1)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: t‐PA plus nitroglycerin (group 2)
Number of subjects: 47
Study: 3035878

Group type: EXPERIMENTAL
Intervention: Zimeldine, 100 mg, b.i.d., n = 40
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Maprotiline, 75 mg, b.i.d., n = 35
Number of subjects: 75
Study: 29196928

Group type: EXPERIMENTAL
Intervention: L-thyroxine treatment (LT4 group)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo group (SCH group)
Number of subjects: 140
Study: 26882324

Group type: EXPERIMENTAL
Intervention: 3D social virtual world (avatar virtual interaction experimental condition)
Number of subjects: 90

Group type: COMPARATOR
Intervention: 2D social networking site (no avatar virtual interaction control condition)
Number of subjects: 90

Group type: COMPARATOR
Intervention: No intervention (no virtual interaction control condition)
Number of subjects: 90
Study: 23125290

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment (1 or 2 mg/m² · d during puberty)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment with additional GnRH analog (GnRHa) for 2 years
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control group (untreated short SGA adolescents)
Number of subjects: 88
Study: 21645269

Group type: EXPERIMENTAL
Intervention: Intravenous DP-b99, 1.0 mg/kg/day for four consecutive days
Number of subjects: 770

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 770
Study: 19489063

Group type: EXPERIMENTAL
Intervention: Iron sucrose 1000 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 60
Study: 16214379

Group type: EXPERIMENTAL
Intervention: Manual therapy
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Exercise therapy
Number of subjects: 109

Group type: COMPARATOR
Intervention: OARSI response criteria
Number of subjects: 109

Group type: COMPARATOR
Intervention: Patient's global assessment
Number of subjects: 109

Group type: COMPARATOR
Intervention: Manual therapy vs Exercise therapy
Number of subjects: 109
Study: 15330820

Group type: EXPERIMENTAL
Intervention: Indomethacin 100 mg intramuscularly
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo intramuscularly
Number of subjects: 7
Study: 11771747

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine (5 mg patch)
Number of subjects: 8
Study: 9203174

Group type: EXPERIMENTAL
Intervention: Steroid-sensitive nephrotic syndrome (SSNS)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Steroid-resistant nephrotic syndrome
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Nephritic syndromes
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Children with severe tubular abnormalities
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Low molecular weight proteinuria
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: RBP
Number of subjects: 119
Study: 8352356

Group type: EXPERIMENTAL
Intervention: Bright white morning light (more than 2500 lux)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Bright white evening light (more than 2500 lux)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo dim red evening light (less than 10 lux)
Number of subjects: 30
Study: 3275568

Group type: EXPERIMENTAL
Intervention: Rifampin (300-450 mg/day)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 30109672

Group type: EXPERIMENTAL
Intervention: FTD (fotemustine, teniposide and dexamethasone)
Number of subjects: 49

Group type: COMPARATOR
Intervention: HD-MA (high-dose methotrexate plus cytarabine)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: FTD
Number of subjects: 49

Group type: COMPARATOR
Intervention: HD-MA
Number of subjects: 49
Study: 28060012

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART)
Number of subjects: 292

Group type: COMPARATOR
Intervention: No treatment (untreated)
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Overall (both groups)
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Controllers (both treated and untreated)
Number of subjects: 292
Study: 25103870

Group type: EXPERIMENTAL
Intervention: Ofatumumab alone
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Ofatumumab with chemotherapy
Number of subjects: 82

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 82
Study: 22730954

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Supportive Listening
Number of subjects: 94
Study: 22010780

Group type: EXPERIMENTAL
Intervention: Kudzu root extract
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18434299

Group type: EXPERIMENTAL
Intervention: 4 mm cryocatheter
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: 6 mm cryocatheter
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Cryoablation with complete slow pathway block
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Cryoablation with incomplete slow pathway block
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Cryoablation with atrial echo beats present
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Cryoablation
Number of subjects: 160
Study: 22169408

Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400mg
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 15673460

Group type: EXPERIMENTAL
Intervention: Caffeine consumption; specific dosage and duration not mentioned.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nicotine consumption; specific dosage and duration not mentioned.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no intervention); specific details not mentioned.
Number of subjects: 0
Study: 12359687

Group type: EXPERIMENTAL
Intervention: Olanzapine augmentation for 8 weeks
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo administration for 8 weeks
Number of subjects: 19
Study: 9615879

Group type: EXPERIMENTAL
Intervention: 4% pure ethanol solution
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: 10% pure ethanol solution
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: 40% pure ethanol solution
Number of subjects: 47

Group type: COMPARATOR
Intervention: Isotonic saline (control)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Beer
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: White wine
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Whisky
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control (isotonic saline)
Number of subjects: 47
Study: 8575493

Group type: EXPERIMENTAL
Intervention: Orchidectomy plus cyproterone acetate 50 mg 3 times a day
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Stilboestrol 1 mg daily
Number of subjects: 328

Group type: COMPARATOR
Intervention: Orchidectomy
Number of subjects: 328
Study: 2917112

Group type: EXPERIMENTAL
Intervention: Nitrous oxide at 0.6 MAC
Number of subjects: 8

Group type: COMPARATOR
Intervention: Isoflurane at 0.6 MAC
Number of subjects: 8
Study: 1181361

Group type: EXPERIMENTAL
Intervention: Exercise group
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Social group
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 23
Study: 29788732

Group type: EXPERIMENTAL
Intervention: SLN intra‐operative histopathological assessment
Number of subjects: 1284

Group type: COMPARATOR
Intervention: No routine SLN intra‐operative histopathological evaluation
Number of subjects: 1284
Study: 28417835

Group type: EXPERIMENTAL
Intervention: EANx
Number of subjects: 8

Group type: COMPARATOR
Intervention: Air
Number of subjects: 8
Study: 25115966

Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 3602

Group type: COMPARATOR
Intervention: Heparin plus glycoprotein IIb/IIIa inhibitors
Number of subjects: 3602

Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 3602
Study: 23460714

Group type: EXPERIMENTAL
Intervention: Docetaxel plus gefitinib 250 mg/d, orally (arm B)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Docetaxel plus placebo (arm A)
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Docetaxel plus gefitinib (arm B)
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Gefitinib after disease progression in arm A
Number of subjects: 270
Study: 22186854

Group type: COMPARATOR
Intervention: Chlorhexidine gluconate mouthwash
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Turmeric mouthwash
Number of subjects: 100
Study: 19081898

Group type: EXPERIMENTAL
Intervention: VivaStyle Paint On Plus (Ivoclar Vivadent)
Number of subjects: 10
Study: 16140283

Group type: COMPARATOR
Intervention: Acute ketamine (two doses)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Chronic ketamine use
Number of subjects: 80
Study: 12672917

Group type: EXPERIMENTAL
Intervention: Pullulan
Number of subjects: 28

Group type: COMPARATOR
Intervention: Maltodextrin (control)
Number of subjects: 28
Study: 10941967

Group type: EXPERIMENTAL
Intervention: Low-fat milk (1.0 g/dL cow's milk fat)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Partially vegetable fat milk (3.5 g/dL fat; 50% vegetable fat: rapeseed oil)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Full vegetable-fat milk (3.5 g/dL fat; 100% vegetable fat: palm, coconut, and soy oil)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Standard-fat milk (3.5 g/dL cow's milk fat)
Number of subjects: 38
Study: 9219147

Group type: EXPERIMENTAL
Intervention: Imipramine 150 mg/day
Number of subjects: 32

Group type: COMPARATOR
Intervention: Imipramine 10 mg/day (control)
Number of subjects: 32
Study: 1350868

Group type: EXPERIMENTAL
Intervention: Combined neural and hormonal blockade (somatostatin and etomidate with thoracic epidural analgesia)
Number of subjects: 24

Group type: COMPARATOR
Intervention: No blockade (control group)
Number of subjects: 24
Study: 6431142

Group type: EXPERIMENTAL
Intervention: PS‐K
Number of subjects: 435

Group type: EXPERIMENTAL
Intervention: FT‐207
Number of subjects: 435

Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 435

Group type: EXPERIMENTAL
Intervention: In‐vitro lymphocyte responsiveness study
Number of subjects: 435

Group type: EXPERIMENTAL
Intervention: Immunofluorescent study
Number of subjects: 435
Study: 29309951

Group type: EXPERIMENTAL
Intervention: Active participant-observer group (AP-O group)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Observer group (O group)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 104
Study: 28007201

Group type: EXPERIMENTAL
Intervention: Initial PCI
Number of subjects: 1800

Group type: COMPARATOR
Intervention: Initial CABG
Number of subjects: 1800

Group type: EXPERIMENTAL
Intervention: Repeat revascularization after initial PCI
Number of subjects: 1800

Group type: COMPARATOR
Intervention: Repeat revascularization after initial CABG
Number of subjects: 1800
Study: 25632806

Group type: EXPERIMENTAL
Intervention: Pinaverium (50 mg, 3 times/day)
Number of subjects: 427

Group type: COMPARATOR
Intervention: Placebo (3 times/day)
Number of subjects: 427
Study: 22943846

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 18

Group type: COMPARATOR
Intervention: Sham Acupuncture
Number of subjects: 18
Study: 20638563

Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg twice a day
Number of subjects: 4484

Group type: COMPARATOR
Intervention: Diclofenac slow release 75 mg twice a day plus omeprazole 20 mg once a day
Number of subjects: 4484
Study: 17662503

Group type: EXPERIMENTAL
Intervention: Naturalistic dieting for 4 weeks
Number of subjects: 157

Group type: COMPARATOR
Intervention: Control group (eat as they normally do when not dieting)
Number of subjects: 157
Study: 16344218

Group type: EXPERIMENTAL
Intervention: 0.18% isotretinoin
Number of subjects: 70

Group type: COMPARATOR
Intervention: 0.05% isotretinoin
Number of subjects: 70
Study: 15116084

Group type: EXPERIMENTAL
Intervention: Red carrots (5 mg/day)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Tomato paste (20 mg/day)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Red carrots (2.6 mg/day)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Tomato paste (5 mg/day)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Tomato paste plus white carrots (5 mg/day)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Mixed dietary sources of lycopene (2 mg/day)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Mixed dietary sources of lycopene (>/=20 mg/day)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Lycopene from red carrots
Number of subjects: 19
Study: 11297716

Group type: EXPERIMENTAL
Intervention: Cognitive intervention designed to reduce anxiety/distress responses to the doxapram injection
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Doxapram-induced hyperventilation
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Panic patients
Number of subjects: 16
Study: 9142004

Group type: EXPERIMENTAL
Intervention: Cold Pressor Test (CPT) during lower-body negative pressure (LBNP)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Cold Pressor Test (CPT) during hemodialysis
Number of subjects: 22

Group type: COMPARATOR
Intervention: Lower-body negative pressure (LBNP) alone
Number of subjects: 22
Study: 7971299

Group type: EXPERIMENTAL
Intervention: Version 2 digital test
Number of subjects: 208
Study: 3499486

Group type: EXPERIMENTAL
Intervention: 100 Hz TENS
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 2 Hz TENS
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 100 Hz vibration
Number of subjects: 40

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 40
Study: 30317264

Group type: EXPERIMENTAL
Intervention: Fat phobia scale
Number of subjects: 2100

Group type: EXPERIMENTAL
Intervention: Attitudes toward obese persons scale
Number of subjects: 2100

Group type: EXPERIMENTAL
Intervention: Correlation between fat phobia scale, attitudes toward obese persons scale, and health‐promoting lifestyle profile II scale scores
Number of subjects: 2100
Study: 26098271

Group type: EXPERIMENTAL
Intervention: High-efficacy condition
Number of subjects: 44

Group type: COMPARATOR
Intervention: Low-efficacy condition
Number of subjects: 44
Study: 25359327

Group type: EXPERIMENTAL
Intervention: One-step self-etch adhesive (Xeno III)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Two-step etch-and-rinse adhesive (Excite)
Number of subjects: 78
Study: 24164227

Group type: EXPERIMENTAL
Intervention: ASK (tobacco screening)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: ADVISE (tobacco advising)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Tobacco use identification
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Associations with ASK and ADVISE
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Practice characteristics
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Proportion of tobacco users in the practice
Number of subjects: 190
Study: 20576390

Group type: EXPERIMENTAL
Intervention: Intravenous systemic administration of tPA within 4.5 hours
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thrombolysis within 4.5 hours
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control groups from ECASS II and ATLANTIS studies
Number of subjects: 0
Study: 19202718

Group type: EXPERIMENTAL
Intervention: Culturally-specific dance intervention, 2 times per week for 8 weeks
Number of subjects: 126

Group type: COMPARATOR
Intervention: Comparison group (control)
Number of subjects: 126
Study: 16595102

Group type: EXPERIMENTAL
Intervention: Comprehensive programme of secondary prevention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 0
Study: 12891263

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 0
Study: 10636365

Group type: EXPERIMENTAL
Intervention: Stenting with abciximab
Number of subjects: 2399

Group type: COMPARATOR
Intervention: Stenting with placebo
Number of subjects: 2399

Group type: EXPERIMENTAL
Intervention: Combined endpoint of death or large myocardial infarction for stenting with abciximab
Number of subjects: 2399

Group type: COMPARATOR
Intervention: Combined endpoint of death or large myocardial infarction for stenting with placebo
Number of subjects: 2399

Group type: COMPARATOR
Intervention: Balloon angioplasty with abciximab
Number of subjects: 2399

Group type: EXPERIMENTAL
Intervention: Cost-effectiveness of stenting plus abciximab
Number of subjects: 2399
Study: 7793195

Group type: EXPERIMENTAL
Intervention: Desflurane 1.0‐4.5% and oxygen (n = 40)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Nitrous oxide 30‐60% in oxygen (n = 40)
Number of subjects: 80
Study: 1903918

Group type: EXPERIMENTAL
Intervention: Flecainide (0.15 mg.kg‐1.h‐1 after a loading dose of 2 mg.kg‐1)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Digoxin (10 micrograms.kg‐1 for 12 hours, then 0.25 mg.24 h‐1)
Number of subjects: 30
Study: 7030978

Group type: EXPERIMENTAL
Intervention: Oxdralazine
Number of subjects: 31

Group type: COMPARATOR
Intervention: Dihydralazine
Number of subjects: 31
Study: 31704050

Group type: EXPERIMENTAL
Intervention: Vitamin D-calcium supplementation
Number of subjects: 178

Group type: COMPARATOR
Intervention: Non-vitamin D group
Number of subjects: 178
Study: 30247967

Group type: EXPERIMENTAL
Intervention: Self-Care Toolkit (SCT)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 100
Study: 26945825

Group type: EXPERIMENTAL
Intervention: PEG + Asc
Number of subjects: 200

Group type: COMPARATOR
Intervention: SPMC
Number of subjects: 200
Study: 26363825

Group type: EXPERIMENTAL
Intervention: Mifepristone (25mg every 12h for 3 days and 600μg buccal misoprostol on the morning of the fourth day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (vacuum aspiration)
Number of subjects: 40
Study: 23631765

Group type: EXPERIMENTAL
Intervention: Counterintuitive concepts with one violation (Experiment 1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Counterintuitive concepts with two violations (Experiment 2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Counterintuitive concepts with three violations (Experiment 3)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intuitive concepts
Number of subjects: 0
Study: 20939675

Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine (NAC) plus clomiphene citrate (CC)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Metformin plus clomiphene citrate (CC)
Number of subjects: 192
Study: 18230694

Group type: EXPERIMENTAL
Intervention: Rosiglitazone (4 mg daily for 7 days)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Water immersion
Number of subjects: 20
Study: 16596921

Group type: EXPERIMENTAL
Intervention: Therapists with master's level postgraduate studies
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Therapists choosing not to refer patients due to concern for poor medical prognosis
Number of subjects: 18
Study: 15163387

Group type: EXPERIMENTAL
Intervention: Perindopril treatment group
Number of subjects: 58

Group type: COMPARATOR
Intervention: Routine treatment group
Number of subjects: 58
Study: 10377639

Group type: EXPERIMENTAL
Intervention: Nonfluoridated resin composite with fluoridated dentifrice
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Fluoridated resin composite with fluoridated dentifrice
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Resin-modified glass ionomer restorative materials with fluoridated dentifrice
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Resin-modified glass ionomer cement with nonfluoridated dentifrice
Number of subjects: 21

Group type: COMPARATOR
Intervention: Nonfluoridated resin composite control with nonfluoridated dentifrice
Number of subjects: 21